ËÄÉ«AV

PowdAir

A simple, easy to use and efficient capsule-based dry powder inhaler with high performance.

In 2010, ËÄÉ«AV decided to develop a reusable, capsule based, low cost dry powder inhaler to deliver large drug doses.

PowdAir can deliver lactose-based or particle-engineered powders, and ËÄÉ«AV has effective experience in both types of formulations, from proof of concept, to optimization, robustness and compatibility tests, scale-up, method validation, stability studies and clinical supplies.

Ìý

Effective delivery - Model Formulation

Ìý

Ìý

Ìý

Ìý

The minimum flow rate at whichÌýPowdAirÌýhas been shown to deliver 95% of the nominal dose is 30 liters per minute of airflow. Above 30 liters per minute, performance is unaffected.

Drug payloads range from the microgram range, employing lactose based formulations.

Ìý

Comprehensive Intellectual Property Position

PowdAirÌýis a patent protected device filed and granted in over 40 countries, including US (US 8677992) and EU (EP 2546460). In addition, other patents have been filed to cover additional scientific matter and the examination process is presently ongoing.

Ìý

Applications

PowdAirÌýdevice is simple, reusable and highly cost-effective device on a global scale. This DPI is indicated for applications where a chronic or a medium term acute capsule based delivery of an API is needed. Examples include COPD/asthma drugs, antibiotics for lung infection, analgesic drugs, pulmonary hypertension drugs, as well as respiratory therapy drugs.

Ìý

Licensing and services

PowdAirÌýis available for licensing fromÌý.

ËÄÉ«AV can provide all formulation development services, capsule filling and tailor a drug product to theÌýÌýdevice or to any other dry powder inhaler. As an integrated inhalation products developer, ËÄÉ«AV possesses the most complete service offering, from API through particle design to formulation development and clinical supplies, for development, scale-up and industrial manufacturing, including full analytical support.

Ìý

Key Advantages

• Capsule basedÌýhigh efficiencyÌýre-usable inhaler.
• Clinical trial ready and industrial manufacturing ready.
• Lowest number of parts on the market (4 parts) for improved manufacturability in the industry - no metal parts, blades or springs
• Patent life until 2034

Ìý

Applications

• Asthma, antibiotics, COPD, CF, others

Ìý

PowdAirÌýis available for clinical trail supply and for licensing. For additional information, please visitÌýÌýorÌýContact us.

Ìý